Arca
Skip to content

Warning Letter to Essential Pharmacy Compounding

Drugs. See Essential Pharmacy Compounding's company page or this site's inspections.

On Jul 11, 2019, FDA's CDER sent Essential Pharmacy Compounding a warning letter.

  • Letter date: Jul 11, 2019
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Dear Mr. Kohll,

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter dated March 10, 2016 (Case #489638), which was issued under your firm’s former name, Essential Pharmacy Compounding. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Nicholas F. Lyons Director Compliance Branch Division of Pharmaceutical Quality Operations III

Record

Recipient
Justin M. Kohll
FDA site ID (FEI)
3003718003
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.